Novel targeted microbubble contrast medium

A technology for targeting microbubbles and contrast agents, applied in the field of biomedical engineering, can solve the problems of weak tissue penetration, low concentration, and limit the clinical application of targeted imaging, achieving broad practical application prospects and enhancing imaging effects. Effect

Inactive Publication Date: 2008-12-03
许川山
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although studies at home and abroad have found that this new non-invasive imaging technology shows good development prospects in the field of early qualitative localization diagnosis of diseases, the antibody-modified targeted microbubble contrast agent developed at this stage is too large because of its molecular weight. When used in vivo, there are generally defects such as weak tissue penetration, low concentration that actually reaches the target area after intravenous injection, and unsatisfactory imaging effects, which severely limit the clinical practical application of targeted imaging.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel targeted microbubble contrast medium
  • Novel targeted microbubble contrast medium

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0019] Example 1: Preparation of sulfatide-modified microbubble contrast agent

[0020] Dissolve 0.28g of lecithin, 0.12g of cholesterol, sulfatide (3mg) and phosphoethanolamine (5mg) in a solution of chloroform and methanol (2:1), evaporate for 30 minutes by rotary evaporation, remove the film and add 10ml of normal saline, Sonicate at room temperature for 10 minutes, homogenize at high speed for 5 minutes, and then sonicate for 10 minutes to prepare a sulfatide-modified microbubble contrast agent. (Such as figure 1 ).

example 2

[0021] Example 2: Enhancement Effect of Sulfatide Modified Microbubble Contrast Agent on Ultrasound Imaging

[0022] Take the New Zealand White Rabbit VX that I copied successfully 2 Liver tumor model (New Zealand white rabbits from the Experimental Animal Center of Chongqing Medical University) was used as the experimental object, and New Zealand white rabbits were anesthetized by intramuscular injection of 4% pentobarbital sodium (1ml / kg), fixed in the supine position, and self-control before and after Methods Before imaging, 1ml of sulfatide-modified microbubble contrast agent was injected into rabbits through the ear along the vein, and the imaging effect of rabbit liver tumors was observed. As a result, it was found that there was obvious aggregation at the tumor site at 12 hours. (Such as figure 2 A. figure 2 B).

example 3

[0023] Example 3: Enhancement effect of sulfatide-modified microbubble contrast agent on CT and MRI imaging with high drug loading and good contrast effect

[0024] During the preparation of the sulfatide-modified microbubble contrast agent, manganese porphyrin (1mg porphyrin manganese / 5ml microbubble) was added to obtain a microbubble contrast agent with a drug loading amount up to 99%. 24 New Zealand white rabbits (from the Experimental Animal Center of Chongqing Medical University) were selected as the experimental subjects, 6 rabbits in each group, and CT and MRI imaging experiments were performed respectively. It was found that the contrast agent obtained in the experiment can not only significantly enhance the effect of CT imaging, but also significantly enhance the effect of MRI imaging.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Login to view more

Abstract

The invention belongs to the biomedical engineering field, in particular relating to a novel targeted microbubble contrast agent. The microbubble contrast agent modified by sulfatides is synthesized by adding the sulfatides during the preparation process of microbubbles, and can be targetedly accumulated in a target tissue during the use to enhance the imaging effect of the target issue, and is expected to be developed into the novel targeted microbubble contrast agent.

Description

technical field [0001] The invention belongs to the field of biomedical engineering, more specifically, the invention relates to a novel targeting microbubble contrast agent. Background technique [0002] Medical imaging has been studied for a hundred years, and imaging technologies emerge in endlessly. Of course, whether it is traditional imaging techniques such as X-rays, ultrasound, computerized tomography (CT), or modern molecular imaging techniques such as magnetic resonance imaging (MRI), they have made great contributions to the development of basic medicine and clinical medicine. . In recent years, with the continuous deepening of research on microbubble contrast agents, the liquid fluorocarbon emulsion microbubble contrast agent obtained by changing the film-forming material and core material can significantly enhance the ultrasound and CT images of the target area; by adding Gd-DTPA can also enhance the MRI image of the target area. Therefore, the application of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K49/18A61K49/04A61K49/10
Inventor 许川山夏新蜀刘学兵刘志君
Owner 许川山
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products